MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)—- $anro #cns–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. “During the third quarter, we continued to advance our clinical programs and strengthened our financial position ahe
